乙酰半胱氨酸活性炭微囊对肝纤维化大鼠的保护作用  

Protective Effect of Activated Carbon N-Acetylcysteine Microcapsule on Liver Fibrosis in Rats

作　　者：方红英[1] 庄让笑[1] 席建军[1] 王福根[1] 孙晶晶[1] 潘旭旺[1] 史婷婷[1] 

机构地区：[1]浙江中医药大学附属杭州西溪医院,杭州310023

出　　处：《中国现代应用药学》2016年第8期993-996,共4页Chinese Journal of Modern Applied Pharmacy

基　　金：杭州市科技计划项目(20110833B17;20130633B09)

摘　　要：目的初步研究乙酰半胱氨酸活性炭微囊(activated carbon N-acetylcysteine microcapsule,ACNAC)对肝纤维化模型大鼠保护作用。方法以二甲基亚硝胺建立SD大鼠肝纤维化模型,ACNAC按剂量20,40,80 mg·kg?1(按乙酰半胱氨酸计算)每日分别灌胃进行治疗,8周后处死大鼠,检测各组大鼠血清学ALT、AST指标,肝组织TGF-β1指标。结果病理结果显示肝纤维化造模处于Ⅲ-Ⅳ期;与模型组比较,各药物治疗组血清ALT、AST有明显好转,且肝组织TGF-β1的表达明显受到抑制。结论 ACNAC对大鼠肝纤维化具有较好的治疗作用,其效果优于乙酰半胱氨酸和水飞蓟宾。OBJECTIVE To investigate the protective effect of the activated carbon N-acetylcysteine microcapsule（ACNAC） on liver fibrosis in rats. METHODS The model of the liver fibrosis on SD rats was constructed by dimethylnitrosamine, and the model rats were treated by ACNAC gavage with a daily dose of 20, 40, and 80 mg·kg^-1, all the rats were sacrificed after 8 weeks, and the contents of ALT, AST in serum and TGF-β1 in hepatic tissue were detected. RESULTS Pathology results showed that the liver fibrosis model was at the stage of Ⅲ-Ⅳ, compared to the model group, the contents of ALT, AST in plasma were improved significantly and the expression of TGF-β1 in hepatic tissue was drastically suppressed, especially in the high dose of ACNAC. CONCLUSION ACNAC has a better therapeutic effect on rats liver fibrosis compared to N-acetylcysteine and silymarinⅠ.

关 键 词：乙酰半胱氨酸活性炭微囊 乙酰半胱氨酸 肝纤维化 

分 类 号：R965.2[医药卫生—药理学]